← Leaderboards
Michael W Andreeff
University Of Tx Md Anderson Can Ctr
$17,991,896
Attributed
$18,901,916
Total exposure
19
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,468,381 · 18
FDA$1,771,403 · 2
By mechanism
P01$29,277,076 · 7
P30$9,171,814 · 3
R01$2,511,854 · 3
P50$2,184,654 · 4
R21$1,060,636 · 2
R03$33,750 · 1
Top collaborators
- Jo Ishizawa4 shared
- Marina Y Konopleva2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Xiaodong Cheng$20,199,960
- Taiping Chen$5,535,689
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisCellsFlow CytometryStem CellsSignal TransductionProteinsBaseSingle Cell AnalysisLeukemiaApoptoticResponseClinical TrialsProgramsCancer CellInhibitor/AntagonistMdm2 GeneGenesMolecularMimeticsResearch PersonnelMediatingRelapseLeukemic CellResistance
Grant awards (86)
07 Flow Cytometry and Cellular Imaging Facility$812,239
P30 · FY2025 · CA · contact PI
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)$460,702
R01 · FY2025 · FD · contact PI
07 Flow Cytometry and Cellular Imaging Facility$763,839
P30 · FY2024 · CA · contact PI
07 Flow Cytometry and Cellular Imaging Facility$720,306
P30 · FY2023 · CA · contact PI
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)$373,673
R01 · FY2023 · FD · contact PI
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML$222,661
R21 · FY2023 · CA · contact PI
07 Flow Cytometry and Cellular Imaging Facility$720,306
P30 · FY2022 · CA · contact PI
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML$189,338
R21 · FY2022 · CA · contact PI
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)$87,029
R01 · FY2022 · FD · contact PI
07 Flow Cytometry and Cellular Imaging Facility$720,306
P30 · FY2021 · CA · contact PI
07 Flow Cytometry and Cellular Imaging Facility$719,076
P30 · FY2020 · CA · contact PI
07 Flow Cytometry and Cellular Imaging Facility$720,306
P30 · FY2019 · CA · contact PI
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)$249,999
R01 · FY2019 · FD · contact PI
07 Flow Cytometry and Cellular Imaging Facility$5,456
P30 · FY2019 · CA · contact PI
Targeting Microenvironment / Leukemia Cell Interactions in CML$185,911
P01 · FY2014 · CA · contact PI
Targeting Microenvironment / Leukemia Cell Interactions in CML$282,957
P01 · FY2013 · CA · contact PI
P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia$196,339
P50 · FY2013 · CA · contact PI
Flow Cytometry$530,009
P30 · FY2012 · CA · contact PI
P53 Activation as Novel Therapeutic Stratgey for Acute Myelogenous Leukemia$221,325
P50 · FY2012 · CA · contact PI
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta$200,000
R01 · FY2012 · FD · contact PI
Targeting Microenvironment / Leukemia Cell Interactions in CML$193,030
P01 · FY2012 · CA · contact PI
Flow Cytometry$2,882
P30 · FY2012 · CA · contact PI
THE THERAPY OF AML$2,401,083
P01 · FY2011 · CA · contact PI
Flow Cytometry$540,453
P30 · FY2011 · CA · contact PI
Targeting Regulators of Apoptosis in AML$341,150
P01 · FY2011 · CA · contact PI
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia$312,240
R21 · FY2011 · CA · contact PI
P53 Activation as Novel Therapeutic Stratgey for Acute Myelogenous Leukemia$268,501
P50 · FY2011 · CA · contact PI
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta$200,000
R01 · FY2011 · FD · contact PI
Targeting Microenvironment / Leukemia Cell Interactions in CML$189,830
P01 · FY2011 · CA · contact PI
Fluorescence-Activated Cell Sorting (FACS) and Molecular Cytogenetics (FISH)$148,622
P01 · FY2011 · CA · contact PI
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma$64,753
P50 · FY2011 · CA · contact PI
THE THERAPY OF AML$2,483,417
P01 · FY2010 · CA · contact PI
Flow Cytometry$563,202
P30 · FY2010 · CA · contact PI
Targeting Regulators of Apoptosis in AML$354,155
P01 · FY2010 · CA · contact PI
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia$336,397
R21 · FY2010 · CA · contact PI
P53 Activation as Novel Therapeutic Stratgey for Acute Myelogenous Leukemia$265,624
P50 · FY2010 · CA · contact PI
Targeting Microenvironment / Leukemia Cell Interactions in CML$196,061
P01 · FY2010 · CA · contact PI
Fluorescence-Activated Cell Sorting (FACS) and Molecular Cytogenetics (FISH)$153,219
P01 · FY2010 · CA · contact PI
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma$68,059
P50 · FY2010 · CA · contact PI
THE THERAPY OF AML$2,440,745
P01 · FY2009 · CA · contact PI
Flow Cytometry$566,884
P30 · FY2009 · CA · contact PI
Targeting Regulators of Apoptosis in AML$349,419
P01 · FY2009 · CA · contact PI
Treatment of Metastatic Breast Cancer with Gene Modified Mesenchymal Stem Cells$326,275
P50 · FY2009 · CA · contact PI
P53 Activation as Novel Therapeutic Stratgey for Acute Myelogenous Leukemia$290,026
P50 · FY2009 · CA · contact PI
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta$200,000
R01 · FY2009 · FD · contact PI
Fluorescence-Activated Cell Sorting (FACS) and Molecular Cytogenetics (FISH)$150,095
P01 · FY2009 · CA · contact PI
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma$67,984
P50 · FY2009 · CA · contact PI
THE THERAPY OF AML$2,374,635
P01 · FY2008 · CA · contact PI
Flow Cytometry$359,564
P30 · FY2008 · CA · contact PI
Targeting Regulators of Apoptosis in AML$348,258
P01 · FY2008 · CA · contact PI
Treatment of Metastatic Breast Cancer with Gene Modified Mesenchymal Stem Cells$219,652
P50 · FY2008 · CA · contact PI
P53 Activation as Novel Therapeutic Stratgey for Acute Myelogenous Leukemia$196,116
P50 · FY2008 · CA · contact PI
Fluorescence-Activated Cell Sorting (FACS) and Molecular Cytogenetics (FISH)$148,517
P01 · FY2008 · CA · contact PI
THE THERAPY OF AML$2,404,845
P01 · FY2007 · CA · contact PI
Targeting Regulators of Apoptosis in AML$345,826
P01 · FY2007 · CA · contact PI
Fluorescence-Activated Cell Sorting (FACS) and Molecular Cytogenetics (FISH)$146,387
P01 · FY2007 · CA · contact PI
THERAPY OF AML$2,435,347
P01 · FY2005 · CA
THERAPY OF AML$2,365,672
P01 · FY2004 · CA
Anti-Leukemic Activity of the Novel Triterpeniod CDDO$251,815
R01 · FY2004 · CA
THERAPY OF AML$2,297,886
P01 · FY2003 · CA
Anti-Leukemic Activity of the Novel Triterpeniod CDDO$234,851
R01 · FY2003 · CA
THERAPY OF AML$2,240,803
P01 · FY2002 · CA
Anti-Leukemic Activity of the Novel Triterpeniod CDDO$253,785
R01 · FY2002 · CA
CORE--FLUORESCENCE ACTIVATED CELL SORTING$0
P01 · FY2002 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$0
P30 · FY2002 · CA
TARGETING REGULATORS OF APOPTOSIS IN AML$0
P01 · FY2002 · CA
CORE--CELL ANALYSIS AND FACS$0
P01 · FY2002 · CA
THERAPY OF AML$2,192,972
P01 · FY2001 · CA
THERAPY OF AML$430,000
P01 · FY2001 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$254,104
P30 · FY2001 · CA
CORE--FLUORESCENCE ACTIVATED CELL SORTING$0
P01 · FY2001 · CA
CORE--CELL ANALYSIS AND FACS$0
P01 · FY2001 · CA
TARGETING REGULATORS OF APOPTOSIS IN AML$0
P01 · FY2001 · CA
REGULATION OF PROLIFERATION AND APOPTOSIS IN LEUKEMIA PROGENITOR CELLS$0
P01 · FY2001 · CA
CORE--FLUORESCENCE ACTIVATED CELL SORTING (FACS)$0
P01 · FY2001 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$0
P30 · FY2001 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$0
P30 · FY2001 · CA
THERAPY OF AML$1,270,463
P01 · FY2000 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$332,337
P30 · FY2000 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$332,337
P30 · FY2000 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$254,104
P30 · FY2000 · CA
CORE--AUTOMATED CYTOMETRY &CELL SORTER LABORATORY/CONFOCAL MICROSCOPY$254,104
P30 · FY2000 · CA
REGULATION OF PROLIFERATION AND APOPTOSIS IN LEUKEMIA PROGENITOR CELLS$163,224
P01 · FY2000 · CA
CORE--FLUORESCENCE ACTIVATED CELL SORTING (FACS)$163,224
P01 · FY2000 · CA
CORE--CELL ANALYSIS AND FACS$79,323
P01 · FY2000 · CA
BCL2 AND P53 IN CYTO PROTEC OF AML CELLS FROM APOPTOSIS$33,750
R03 · FY2000 · TW